By Louis Garguilo, Chief Editor, Outsourced Pharma
Over the years, I’ve heard a fair share of aphoristic statements on how biopharma organizations should approach CDMO relationships. The one above, delivered by Lisa Wyman, SVP technical operations, Acceleron Pharma, ranks among the most intriguing — and potentially powerful — if put into practice. How do you so position your CDMOs? Wyman explains via some workable ideas and a few more precise and enlightening statements.